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Neuropilin 1 (NRP1) plays an important but ill-defined
role in VEGF-A signaling and vascular morphogen-
esis. We show that mice with a knockin mutation
that ablates the NRP1 cytoplasmic tail (Nrp1cyto)
have normal angiogenesis but impaired develop-
mental and adult arteriogenesis. The arteriogenic
defect was traced to the absence of a PDZ-depen-
dent interaction between NRP1 and VEGF receptor
2 (VEGFR2) complex and synectin, which delayed
trafficking of endocytosed VEGFR2 from Rab5+ to
EAA1+ endosomes. This led to increased PTPN1
(PTP1b)-mediated dephosphorylation of VEGFR2 at
Y1175, the site involved in activating ERK signaling.
The Nrp1cyto mutation also impaired endothelial tu-
bulogenesis in vitro, which could be rescued by ex-
pressing full-length NRP1 or constitutively active
ERK. These results demonstrate that the NRP1 cyto-
plasmic domain promotes VEGFR2 trafficking in a
PDZ-dependent manner to regulate arteriogenic
ERK signaling and establish a role for NRP1 in
VEGF-A signaling during vascular morphogenesis.
INTRODUCTION
Vascular morphogenesis requires the three complementary pro-
cesses of vasculogenesis, angiogenesis, and arteriogenesis. All
three are VEGF-A dependent, but how VEGF-A signaling is
regulated at the molecular level to selectively stimulate each
process at the appropriate time is poorly understood (Carmeliet
and Jain, 2011). VEGF-A exerts its biological effects by binding
to its tyrosine kinase (TK) receptors VEGFR1 and VEGFR2 and
the non-TK receptor neuropilin 1 (NRP1) (Koch et al., 2011). In
endothelial cells, VEGFR1 is thought to function as a ‘‘decoy’’ re-
ceptor, whereas VEGFR2 is the main signal transducer of all ma-
jor biological effects, including endothelial cell proliferation,
migration, and survival. NRP1 was first identified as a sema-
phorin 3A receptor, but can also bind the VEGF-A165 isoform of156 Developmental Cell 25, 156–168, April 29, 2013 ª2013 Elsevier IVEGF-A with high affinity (Koch, 2012). Although NRP1’s precise
role in VEGF-A signaling in vivo has not been defined, its extra-
cellular domain is thought to act in a manner similar to other cor-
eceptors, such as syndecans and glypicans, by increasing the
local plasma membrane concentration of VEGF-A and thereby
promoting its binding to VEGFR2 (Koch, 2012; Koch et al.,
2011; Sorkin and von Zastrow, 2009).
NRP1 possesses a short cytoplasmic domain that contains a
PDZ-binding domain at its C terminus (Wang et al., 2006).
Yeast-two hybrid studies identified the PDZ-domain protein
synectin (also known as neuropilin 1-binding protein NIP or
GIPC1) as a binding partner for the NRP1 cytoplasmic tail (Cai
and Reed, 1999), and this interaction has been confirmed in
endothelial cells (Prahst et al., 2008). Synectin is an essential
regulator of arterial morphogenesis that acts by promoting
VEGFR2 endocytosis and signaling (Chittenden et al., 2006;
Lanahan et al., 2010). However, it remains unknown how
VEGFR2 interacts with synectin, as it lacks a PDZ binding
domain. One possibility is that the adaptor protein APPL1 cou-
ples early endosomes containing VEGFR2 to the cytoplasmic
trafficking machinery, as it has a PDZ-domain (Lin et al., 2006).
Another possibility is that NRP1 provides this link, as it has the
ability to bind both VEGF-A165 and synectin (Cai and Reed,
1999). To identify if NRP1 plays a specific role in arteriogenesis,
and, in particular, to examine if the NRP1-synectin interaction
promotes VEGF-A-induced VEGFR2 signaling during arterio-
genesis, we studied Nrp1cyto mice that lack the exon that en-
codes the NRP1 cytoplasmic domain.
Nrp1cyto mice are viable and display normal developmental
angiogenesis, with the only abnormality reported to date being
an increased frequency of artery-vein crossings in the retina
(Fantin et al., 2011). We show here that pathological angiogen-
esis is also normal in these mice, whereas, arterial morphogen-
esis, during development and in adults, was significantly
impaired. The observed abnormalities included a reduced num-
ber and branching frequency of small arteries in various organs
and an impaired arteriogenic response after arterial injury.
Furthermore, endothelial cells from Nrp1cyto mice showed
impaired ERK activation in response to VEGF-A165 and ineffi-
ciently assembled endothelial tubules in vitro. We traced these
defects to reduced VEGF-A165-induced trafficking of VEGFR2,
which resulted in its prolonged exposure to the protein tyrosinenc.
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decreased phosphorylation of the VEGFR2 tyrosine Y1175 that
activates ERK signaling. Abnormal ERK signaling in Nrp1cyto
endothelial cells could be rescued by full-length NRP1, but not
NRP1 lacking the cytoplasmic domain or its PDZ-binding
sequence. Furthermore, abnormal endothelial cell (EC) tubulo-
genesis in vitro could be rescued by expression of full-length
NRP1 or constitutively active ERK. These findings establish
NRP1 as a specific regulator of VEGF-A-induced VEGFR2 traf-
ficking and ERK signaling that is essential for VEGF-A-depen-
dent arterial morphogenesis.
RESULTS
To evaluate the role of the NRP1 cytoplasmic domain in post-
natal angiogenesis and arteriogenesis, we studied Nrp1cyto
knockin mice, in which a stop codon in exon 17 prevents trans-
lation of the cytoplasmic domain (Fantin et al., 2011). We first
studied the angiogenic response of these mice in several
different models of postnatal and pathological vessel growth
and then concentrated on developmental and postnatal
arteriogenesis.
Unaltered Pathological Angiogenesis in Nrp1cyto Mice
We have previously shown that the NRP1 cytoplasmic tail is not
essential for normal angiogenesis in the developingmouse retina
(Fantin et al., 2011), a finding confirmed in the present study (Fig-
ures S1A and S1A0 available online). To address if this NRP1
domain is instead required for pathological angiogenesis in this
tissue, we employed amousemodel of oxygen-induced retinop-
athy (Smith et al., 1994). In this assay, 7-day-old mouse pups
with a partially developed retinal vasculature are exposed to
hyperoxia for 5 days. This treatment obliterates immature capil-
laries in the central retina, in particular around arteries with their
high oxygen tension, but does not cause regression of arteries or
veins (Figure S1B, ‘‘vo’’ indicates an area with vasoobliteration).
After return to normoxic room air on day 12, the now poorly vas-
cularized retina becomes hypoxic, upregulates VEGF-A, and
initiates a pathological, neovascular response (Figure S1B,
‘‘nv’’ indicates an area with neovascularization). Specifically,
the neovascular response leads to the longitudinal expansion
of arteries, leading to their tortuous appearance (Figures S1B
and S1B0, arrowhead). At the same time, sprouting from veins
and remaining capillaries leads to the formation of neovascular
tufts (Figure S1B0, straight and curved arrows, respectively).
The pattern of vasoobliteration and neovascularization appeared
similar in Nrp1cyto mice and their wild-type (WT) littermates (Fig-
ures S1B, S1C, S1B0, and S1C0). Quantitation confirmed that
there was no significant difference in vasoobliteration or the neo-
vascular response in both genotypes (Figures S1D and S1E).
We next studied angiogenesis in subcutaneous implants of
growth factor-depleted Matrigel pellets supplemented with
buffer (controls) or the NRP1-binding isoform of VEGF-A,
VEGF-A165. VEGF-A165-loaded pellets induced an equally strong
angiogenic response in control and Nrp1cyto mice after 7 days
(Figures S1F and S1G). Finally, we used a skin wounding model,
in which wound closure is strongly dependent on angiogenesis
(Tonnesen et al., 2000). We found that the rate of wound closure
was similar in control and Nrp1cyto mice over a course of 7 daysDeve(Figures S1H and S1I). Taken together, all three assays show that
the NRP1 cytoplasmic tail is not required for postnatal or patho-
logical angiogenesis.
Impaired Arteriogenesis in Nrp1cyto Mice
We then examined the requirement of the NRP1 cytoplasmic
tail for developmental and adult arteriogenesis. To this end,
we used micro-CT (mCT) to visualize arterial circulation in the
kidneys of neonatal (P7) and in the heart, hindlimbs, and kidneys
of young adult (6–8 weeks of age) mice, using contrast injec-
tions that fill only arterial, but not capillary or venous beds
(Simons, 2008). The mCT images of the arterial circulation and
their quantitative analysis showed a significant reduction in
the number of smaller arteries and arterioles in Nrp1cyto mice
compared to littermate controls in developing renal vasculature
at P7 (Figures 1A and 1B) and in the adult coronary, limb and
renal circulations (Figures 1C–1I). Overall, the pattern of the
arterial tree in Nrp1cyto mice closely resembled that of synectin
null mice (Chittenden et al., 2006). Consistent with an impaired
development of the arterial vascular system in different organs,
adult Nrp1cyto mice showed a small, but significant reduction in
body, kidney, and heart weight (Figure S2A) as well as mCT-
determined kidney and heart size (Figure S2B) compared to
WT littermates.
We next analyzed arteriogenesis in the hindlimb ischemia
model, which was induced by the ligation and removal of a
segment of the common femoral artery, as previously described
(Ren et al., 2010). Blood flow measurements with a deep pene-
trating laser-Doppler probe demonstrated comparable blood
flow before injury and a 90% reduction in perfusion in both
Nrp1cytomutants andWT littermates immediately after induction
of ischemia (Figures 2A and 2B). Although flow recovered over a
period of 2 weeks in control mice, flow recovery in Nrp1cytomice
was reduced as early as day 3, remained at 50% of control
levels at day 14, and had not fully recovered by day 28 (Figures
2A and 2B).
Because arteriogenesis is the key process responsible for
blood flow recovery in this model (Chittenden et al., 2006), we
usedmCT to visualize and quantitate the extent of the arterial cir-
culation (Figures 2C and 2D). We observed a significant
decrease in the density and number of smaller arteries and arte-
rioles both above and below the knee in Nrp1cyto compared to
control mice (Figures 2E and 2F). This difference could not be ex-
plained by low synectin levels, which we have previously shown
to impair arteriogenesis in this experimental setting (Chittenden
et al., 2006) as western blot analysis of normal and ischemic
tissues from both WT and Nrp1cyto mice demonstrated similar
synectin expression (Figure S3A).
Impaired VEGF-A Signaling and ERK Activation in
Nrp1cyto Mice
Impaired arteriogenesis has been linked to decreased activation
of ERK signaling by VEGF-A (Hong et al., 2006; Lanahan et al.,
2010). Indeed, immunofluorescence analysis of forming collat-
erals in the hindlimb ischemia model demonstrated reduced
ERK activation in the endothelium of Nrp1cyto compared to WT
mice (Figure S3B, white arrows). To analyze the contribution of
the NRP1 cytoplasmic tail to this process, we first compared
VEGF-A165-induced ERK activation in Nrp1
cyto and controllopmental Cell 25, 156–168, April 29, 2013 ª2013 Elsevier Inc. 157
Figure 1. Micro-CT Analysis of the Arterial Vasculature Kidney of Neonatal Day 7 Kidney and in Heart, Hindlimb, and Kidney of Adult Nrp1cyto
Mice and Wild-Type Littermates
(A–D) Representative reconstructed micro-CT images of day 7 neonatal kidney and the heart, hindlimb, and kidney of WT and Nrp1cyto mice at 16 mm
resolution.
(E–I) Quantitative analysis of micro-CT images from Nrp1cyto (white bars) and WT (black bars) neonatal kidney and adult heart, hindlimb, and kidney shows a
significant decrease in the total number of <100 mm diameter vessels (mean ± SEM, *p < 0.05).
See also Figures S1 and S2.
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demonstrated a slight increase in Nrp1 levels in the mutant
mice consistent with prior observations (Fantin et al., 2011). In-
jection of 1 mg/kg VEGF-A165 intraperitoneally (i.p.) led to a rapid
upregulation of VEGFR2 phosphorylation at the Y1175 residue
that is involved in the activation of PLCg/ERK signaling in control
mice and was accompanied by increased ERK1/2 phosphoryla-
tion (Figure 3A). Strikingly, both of these responses to VEGF-A165
were markedly reduced in Nrp1cyto hearts (Figure 3A).
To obtain further information on the molecular mechanism
involved in reduced ERK activation after loss of the NRP1 cyto-
plasmic tail, we next examined VEGF-A signaling in primary arte-
rial EC from Nrp1cyto and control mice. As in vivo, NRP1 levels
were slightly elevated in Nrp1cyto EC compared to WT EC,
whereas VEGFR2 expression was similar in EC from both geno-
types (Figure 3B). Compared to WT EC, Nrp1cyto EC showed a
marked decrease in phosphorylation of the VEGFR2 Y1175 site
(Figures 3B and 3C). In agreement with this observation and
our in vivo findings, ERK1/2 phosphorylation was also signifi-
cantly decreased in the mutant primary EC (Figures 3B and 3D).158 Developmental Cell 25, 156–168, April 29, 2013 ª2013 Elsevier ITo investigate whether the reduced ERK activation in Nrp1cyto
EC is specific to impaired VEGF-A signaling, or reflects a broader
signaling defect, we examined the effect of both FGF2 and IGF1
treatment on ERK signaling in primary EC fromNrp1cyto and con-
trol mice. Both growth factors activated ERK similarly in EC from
both genotypes (Figure 3E). These results demonstrate that
impaired ERK1/2 signaling in EC of Nrp1cyto mice is specific to
VEGF-A165-induced VEGFR2 activation.
To exclude that impaired VEGFR2 phosphorylation simply re-
flects a reduced affinity of NRP1cyto for VEGF-A165, we used an
established method that tests binding of NRP1 ligands such as
alkaline phosphatase-conjugated VEGF-A165 to NRP1-express-
ing axons and vessels in vivo (Vieira et al., 2007). Using this
assay, we observed similar binding of VEGF-A165 to axons that
express NRP1, but lack VEGFR2, and to vessels that coexpress
NRP1 and VEGFR2 inNrp1cytomice and controls (Figure S4A). In
contrast, VEGF-A165 failed to bind to axons that lack VEGFR2 in
theNrp1/ brain, as expected (Figure S4B). These results agree
with previous in vitro studies, which used Scatchard analysis to
show a similar affinity of VEGF-A165 for full-length NRP1 andnc.
Figure 2. Nrp1cyto Mice Show Impaired Blood Flow Recovery in the Hindlimb Ischemia Model
(A and B) Blood flow measurements in the HLI model. (A) Doppler imaging demonstrated the level of perfusion in hindlimbs of WT and Nrp1cyto mice before and
after HLI surgery at the indicated time points. (B) Quantitative analysis of laser Doppler images 3 days after HLI surgery in WT (black bars) and in Nrp1cyto mice
(mean ± SEM, *p < 0.05).
(C–F) Micro-CT analysis of arterial diameter in the HLI model. Representative micro-CT images of (C) WT and (D) Nrp1cyto mice 14 days after HLI surgery.
Quantitative micro-CT analysis of arterial vasculature (E) above and (F) below the knee in WT (black bars) and Nrp1cyto mice (white bars) 14 days after HLI
surgery. The total number of <100 mm diameter vessels was significantly decreased in Nrp1cyto mice relative to WT littermates in both the thigh and calf
(mean ± SEM, *p < 0.05).
See also Figure S3.
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2008).
To define if impaired VEGF-A165 signaling inNrp1
cyto EC is due
to the absence of the PDZ-binding domain or another part of the
NRP1 cytoplasmic tail, we transduced primary arterial EC from
Nrp1cyto mice with either a control adenoviral vector (Ad-null)
or vectors expressing full-length NRP1 (Ad-Nrp1), NRP1 lacking
the entire cytoplasmic domain (Ad-Nrp1cyto) or NRP1 lacking
only the PDZ binding site (Ad-Nrp1PDZ). As NRP1cyto expression
levels are variable in vitro (but not in vivo), we chose cells with
NRP1cyto levels that best matched Nrp1 levels following trans-
duction of various mutants noted above (Figure 4A). Although
the full-length Ad-Nrp1 construct restored VEGFR2 Y1175 phos-
phorylation and ERK activation to control levels, both Ad-
Nrp1cyto and Ad-Nrp1PDZ were ineffective (Figures 4A and 4B).
Similar results were obtained with EC from Nrp1 conditional
null (Nrp1fl/fl) mice that were transduced with a CRE-expressing
vector (Ad-Cre) to ablate NRP1 expression and then transduced
with Ad-Nrp1, Ad-Nrp1cyto, or Ad-Nrp1PDZ (Figures 4C and 4D).DeveThus, only the full-length NRP1 construct restored VEGF-
A165-dependent ERK activation in mutant cells to WT levels
(Figures 4B and 4D). Together, these findings establish that the
PDZ-binding region in the NRP1 cytoplasmic domain is essential
for normal VEGFR2 and ERK activation by VEGF-A165 in arterial
endothelial cells.
To link changes in ERK activation in Nrp1cyto EC to the
observed arteriogenesis defects, we used an in vitro 3D tubulo-
genesis assay with human umbilical cord endothelial cells
(HUVEC) that mimics many features of arteriogenesis in vivo
(Koh et al., 2008; Stratman and Davis, 2012; Stratman et al.,
2011). Knocking down NRP1 with siRNA in this model signifi-
cantly impaired tubulogenesis, whereas expression of NRP1,
but not NRP1PDZ or NRP1cyto constructs, restored tubulogenesis
(Figures 4E and 4F). Moreover, defective tubulogenesis in the
presence of NRP1cyto or NRP1PDZ could be rescued by coex-
pression of constitutively active (CA) ERK (Figures 4E and 4F).
Thus, restoring ERK activation is sufficient to restore tubulogen-
esis in Nrp1cyto EC.lopmental Cell 25, 156–168, April 29, 2013 ª2013 Elsevier Inc. 159
Figure 3. Impaired VEGF-A Signaling in
Nrp1cyto Mice
(A) Western blot analysis of heart lysates following
intraperitoneal injection of VEGF-A. Blots show
reduced ERK and VEGFR2 phosphorylation in
Nrp1cyto mice relative to WT littermates.
(B–D) Western blot analysis of cell lysates from pri-
mary arterial EC from Nrp1cyto and WT EC that were
serum-starved and then stimulated for the indicated
times with 50 ng/ml VEGF-A165. (B) Blots show
reduced phosphorylation of VEGFR2 on Y1175 and of
ERK in Nrp1cyto relative to control EC. (C) Quantifica-
tion of the ratio of phospho-VEGFR2 (pVEGFR2)
relative to total VEGFR2 (VEGFR2) (mean ± SD, n = 5,
*p < 0.05). (D) Quantification of the ratio of phospho-
ERK (pERK) relative to total ERK (ERK) (mean ± SD,
n = 5, *p < 0.05).
(E) Western blot analysis of cell lysates from Nrp1cyto
and WT primary arterial EC that were serum-starved
and stimulated for the indicated times with 50 ng/ml of
FGF2 or IGF1. ERK phosphorylation was similar in
Nrp1cyto and WT EC.
See also Figure S4.
Developmental Cell
Neuropilin 1 Regulation of ArteriogenesisDelayed VEGFR2 Trafficking in Nrp1cyto Endothelial
Cells
Previous studies demonstrated that reduced VEGFR2 endocy-
tosis or delayed trafficking reduces its signaling output (Lanahan
et al., 2010). Thus, loss of synectin delays VEGFR2 transit to early
endosomes and reduces ERK signaling (Lanahan et al., 2010).
Because NRP1 has been proposed to be involved in VEGFR2
trafficking (Salikhova et al., 2008; Simons, 2012; Simons and
Eichmann, 2012; Ballmer-Hofer et al., 2011) and binds synectin
through its cytoplasmic tail (Cai and Reed, 1999; Horowitz and
Seerapu, 2012), we evaluated if the NRP1 cytoplasmic domain
is essential for the cotrafficking of NRP1 and VEGFR2 in primary
arterial EC.
A time course analysis of biotinylatedNRP1 inNrp1cyto andWT
EC after exposure to VEGF-A165 showed a comparable extent
and rate of NRP1 uptake (Figures 5A and 5B). The extent and
rate of biotinylated VEGFR2 uptake was also similar in EC from
both genotypes (Figures 5C and 5D). Confocal microscopy
showed that prior to VEGF-A165 stimulation, VEGFR2 and
NRP1 were distributed similarly on the plasma membrane (Fig-
ure S5A) and that the intracellular distribution of NRP1 (Fig-
ure S5B) in EC of both genotypeswas also similar. In both control
and Nrp1cyto EC, VEGF-A165 stimulation led to accumulation of
VEGFR2 and NRP1 in EEA1+ endosomes (Figure 5E). However,
quantitative analysis demonstrated that the colocalization of
VEGFR2 and NRP1 in EEA1+ endosomes was significantly
reduced in Nrp1cyto EC compared to WT EC at 15 min (Figures
5E–5G) and 30 min (Figures 5F, 5G, and S5C) after VEGF-A165
stimulation.
The reduced appearance of both VEGFR2 and NRP1 in EEA1+
endosomes of Nrp1cyto EC after VEGF-A stimulation suggests
that the complex either accumulates in a previous compartment
(Rab5+ sorting endosomes) or moves faster to downstream
compartments (Rab7+ and/or Rab11+ endosomes). To distin-160 Developmental Cell 25, 156–168, April 29, 2013 ª2013 Elsevier Iguish these possibilities, we compared colocalization of
VEGFR2 and NRP1 in peripherally located Rab5+ endosomes
10 min after VEGF-A165 stimulation and in Rab7+ versus
Rab11+ endosomes at 30 min after stimulation. At 10 min, the
VEGFR2/NRP1 complex was present at significantly higher
levels in Rab5+ endosomes inNrp1cyto compared toWT EC (Fig-
ures 6A–6C), suggesting slower clearance of the NRP1cyto/
VEGFR2 compared to the NRP1/VEGFR2 complex from
Rab5+ to EAA1+ endosomes. Even though VEGFR2 and NRP1
were delayed in upstream compartments, VEGFR2 and NRP1
were present at similar levels in Rab7+ endosomes at 30 min
(Figures 6D–6F). These data are also consistent with previous
observations, which suggested accelerated trafficking of
VEGFR2 from EAA1 endosomes to Rab7+ endosomes in the
absence of the NRP1 cytoplasmic tail (Ballmer-Hofer et al.,
2011). Finally, VEGFR2 and NRP1 were present at higher levels
in Rab11+ endosomes in WT compared to Nrp1cyto EC (Figures
6G–6I), again consistent with a delay in trafficking from the Rab5
compartment.
To investigate whether the delayed trafficking of NRP1
and VEGFR2 from Rab5+ sorting to EAA1+ endosomes in
Nrp1cyto EC represents a general defect in clathrin-mediated
endocytosis and trafficking, we studied the transferrin receptor
as a prototypical membrane protein endocytosed via the clathrin
pathway (Sorkin, 2004). We observed similar amounts of trans-
ferrin in EEA1+ endosomes in Nrp1cyto and control EC (Figures
S6A and S6B) demonstrating that the general process of cla-
thrin-mediated endocytosis is normal in EC lacking the NRP1
cytoplasmic tail, and that reduced trafficking from Rab5+
to EAA1+ endosomes is specific to the VEGFR2/NRP1cyto
complex.
To demonstrate that full-length NRP1 is required for efficient
VEGFR2 trafficking and that NRP1 accumulation in Nrp1cyto EC
was not responsible for the observed defects, we transducednc.
Figure 4. Rescue of VEGF-A Signaling in Nrp1cyto and Nrp1fl/fl Primary EC by Full-Length NRP1 and of EC Tubulogenesis following NRP1
siRNA Knockdown with Constitutively Active ERK
(A and B) Western blot analysis of Nrp1cyto EC that were transduced with the indicated adenoviral constructs, serum-starved and stimulated with 50 ng/ml
VEGF-A165. Blots (A) and quantitation of ERK activation (B) show that Ad-Nrp1, but not Ad-Nrp1
cyto or Ad-Nrp1PDZ, restores VEGF-A-induced VEGFR2 and ERK
activation in Nrp1cyto EC (mean ± SD, n = 3, *p < 0.05).
(C and D) Western blot analysis of Nrp1fl/fl EC treated with adenoviral constructs expressing CRE recombinase to inactivate NRP1 were transduced with the
indicated adenoviral constructs, serum-starved and stimulated with 50 ng/ml VEGF-A165. Blots (C) and quantitation (D) show thatAd-Nrp1, but notAd-Nrp1
cyto or
Ad-Nrp1PDZ, restores the activation of VEGFR2 and ERK (mean ± SD, n = 3, *p < 0.05).
(E and F) HUVEC treated with control or NRP1 siRNA were treated with the indicated adenoviral vectors to compare their capacity to undergo tube formation in 3D
collagenmatricesafter 72hr.Representative images (E) andquantification (F) of tubulogenesisafter 72hr (mean±SEM,n=18, *p<0.05).Scalebar represents100um.
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30 min after VEGF-A165 stimulation, the proportion of VEGFR2
in EEA1+ endosomes was significantly higher in Ad-Nrp1 trans-
duced Nrp1cyto EC and similar to control EC (Figures S7A and
S7B). These experiments demonstrate that full-length NRP1 res-
cues defective VEGFR2 trafficking in Nrp1cyto EC.
Delayed VEGFR2 Trafficking in Nrp1cyto EC Reduces
ERK Activation Due to PTP1b-Mediated
Dephosphorylation of VEGFR2 Y1175
We previously reported that delayed VEGFR2 trafficking in syn-
ectin null EC exposes the phosphorylated Y1175 site of VEGFR2
to dephosphorylation by PTP1b (Lanahan et al., 2010). BecauseDeveNrp1cyto EC also demonstrated delayed VEGFR2 trafficking and
reduced Y1175 phosphorylation, we knocked down PTP1b and
several other phosphotyrosine phosphatases known to be
involved in VEGF-A signaling in primary EC (Figures 7A and
7B). As observed for synectin null EC, knockdown of PTP1b in
Nrp1cyto EC restored Y1175 phosphorylation of VEGFR2 to
normal levels (Figure 7C) and reactivated ERK signaling (Figures
7C and 7D). This effect was specific for PTP1b, as knockdown of
several other protein phosphatases did not have this effect (Fig-
ures 7C and 7D).
These results suggest that PTP1b dephosphorylates VEGFR2
in Nrp1cyto EC whereas it lingers in clathrin-coated vesicles or
Rab5+ endosomes in Nrp1cyto EC.lopmental Cell 25, 156–168, April 29, 2013 ª2013 Elsevier Inc. 161
Figure 5. Normal Internalization but Reduced Colocalization of VEGFR2 and NRP1 in EAA1+ Endosomes in Nrp1cyto Arterial EC
(A–D) Western blot analysis of NRP1 and VEGFR2 internalization following cell surface biotinylation and VEGF-A165 stimulation in WT and Nrp1
cyto EC. (A and B)
Blots show internalization at the indicated times. (C and D) Quantification of NRP1 and VEGFR2 internalization at 5, 15, and 30 min following VEGF-A165 stim-
ulation relative to time 0 (mean ± SEM, n = 4).
(E–G) VEGFR2andNRP1colocalization in EAA1+ endosomes in primary arterial EC fromWTandNrp1cytomice after VEGF-A165 stimulation. (E) Confocal images of
EC that were immunolabeled for VEGFR2, NRP1, and EEA1 15 min after stimulation. Scale bar represents 9 mm. Quantification of VEGFR2 (F) and NRP1 (G)
colocalization in EEA1-positive vesicles 15 and 30 min after VEGF-A165 stimulation shows a significant reduction in the number of EEA1 endosomes containing
VEGFR2 inNrp1cyto relative toWTEC (overlap coefficient according toManders, n=10 independent fields for each timepoint andcell type,mean±SEM, *p<0.05).
See also Figure S5.
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of VEGFR2, NRP1, and PTP1b (Figure S8). We therefore used
super resolution structured illumination microscopy (SIM) to
examine whether VEGFR2, NRP1, and PTP1b colocalize to a
common compartment. By employing a fine pattern of illumina-
tion stripes at well-defined positions and analyzing signal varia-
tion in fluorescence as a function of time and position, SIM
achieves8-fold improved volumetric resolution relative to con-
ventional microscopy (Gustafsson et al., 2008; Toomre and
Bewersdorf, 2010). In control EC, VEGFR2 and PTP1b localized
to toroid-shaped structures close to the plasma cell membrane
(Figures 8A and 8A0) that are characteristic of Rab5+ sorting en-
dosome (Galperin et al., 2012; Galperin and Sorkin, 2003). Both
NRP1 andNRP1cyto colocalized with VEGFR2 in these structures
(Figure 8B).
DISCUSSION
The results of this study demonstrate that the NRP1 cytoplasmic
domain is dispensable for angiogenesis, but critical for normal162 Developmental Cell 25, 156–168, April 29, 2013 ª2013 Elsevier Iarteriogenesis in both developmental and adult settings. The ar-
teriogenic function of the NRP1 cytoplasmic domain was traced
to an essential role in VEGFR2 trafficking and further shown to
require PDZ-dependent interactions. The observed trafficking
defect in EC lacking the NRP1 cytoplasmic domain was charac-
terized by delayed trafficking of VEGFR2 from Rab5+ sorting to
EEA1+ endosomes, leading to increased PTP1b-dependent
dephosphorylation of the VEGFR2 Y1175 site that is required
for activation of the PLCg/ERK pathway. The reintroduction of
NRP1 with an intact cytoplasmic domain or the suppression of
PTP1b expression fully restored VEGFR2 trafficking and VEGF-
A-dependent ERK activation.
In a previous study, we demonstrated that the absence of
the NRP1 PDZ-binding partner synectin led to similar develop-
mental and adult arterial morphogenesis defects, decreased
VEGFR2 trafficking, and reduced ERK activation; these
defects were also correctable by suppression of PTP1b activity
or expression (Lanahan et al., 2010). Taken together, these find-
ings establish that NRP1 and synectin together promote the
proper movement of VEGFR2 to EEA1+ endosomes and thatnc.
Figure 6. Impaired VEGFR2 and NRP1 Trafficking in Nrp1cyto Arterial EC
(A–C) Primary arterial EC fromWT andNrp1cytomice were immunolabeled for VEGFR2, NRP1, and Rab5 10min after VEGF-A165 stimulation. Confocal images (A)
(scale bar represents 9 mm) and quantification (B) and (C). The overlap coefficient according to Manders shows that the number of Rab5+ endosomes containing
VEGFR2 and NRP1 is significantly increased in Nrp1cyto relative to WT EC (n = 10 independent fields for each time point and cell type, mean ± SEM, *p < 0.05).
(D–F) Primary arterial EC fromWT andNrp1cytomice were immunolabeled for VEGFR2, NRP1, and Rab7 30min after VEGF-A165 stimulation. Confocal images (D)
(scale bar represents 7 mm) and quantification (E) and (F). The overlap coefficient according to Manders shows that the number of Rab7+ endosomes containing
VEGFR2 and NRP1 is not changed in Nrp1cyto relative to WT EC, even though both proteins accumulate in the upstream Rab5+ compartment in Nrp1cyto EC
(n = 10 independent fields for each time point and cell type, mean ± SEM).
(G–I) Primary arterial EC fromWT andNrp1cytomice were immunolabeled for VEGFR2, NRP1, andRab11 30min after VEGF-A165 stimulation. Confocal images (G)
(scale bar represents 12 mm) and quantification (H) and (I). The overlap coefficient according toManders shows that the number of Rab11+ endosomes containing
VEGFR2 andNRP1 is significantly decreased inNrp1cyto relative toWT EC, as expected, because both proteins accumulate in the upstream Rab5+ compartment
in Nrp1cyto EC (n = 10 independent fields for each time point and cell type, mean ± SEM, *p < 0.05).
See also Figures S6 and S7.
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activation.
VEGF-A signaling has long been recognized as critical for all
aspects of vascular development including vasculogenesis,
angiogenesis, and arteriogenesis. Thus, deletion of VEGF-A,
VEGFR2, or PLCg, an enzyme critical for VEGFR2-dependent
ERK activation, results in early embryonic lethality (Chung and
Ferrara, 2011). Given the central role played by VEGF-A signaling
in the vasculature, it is not surprising that it is tightly controlled atDevemultiple levels. Recent studies have firmly established that re-
ceptor tyrosine kinase signaling is not extinguished after recep-
tor-ligand complex internalization from the plasma membrane,
but continues in various endosomal compartments (Dobrowolski
and De Robertis, 2012; Platta and Stenmark, 2011). VEGFR2 up-
take proceeds in a classical clathrin- and dynamin-dependent
fashion, with much of ERK signaling occurring in EEA1+ endo-
somes (Germain and Eichmann, 2010). Upon endocytosis,
VEGFR2 is initially found in clathrin-coated vesicles, moves onlopmental Cell 25, 156–168, April 29, 2013 ª2013 Elsevier Inc. 163
Figure 7. Rescue of Defective ERK Signaling
in VEGF-A-Stimulated Nrp1cyto Arterial EC by
Knockdown of PTP1b
Primary arterial EC from Nrp1cyto mice transfected
with siRNA specific for the indicated phospha-
tases were serum-starved and then stimulated with
50 ng/ml VEGF-A165.
(A and B) Knockdown of the indicated phosphatases
in Nrp1cyto arterial EC shown by immunoblotting (A);
PTP1b knockdown was quantified in (B), dashed line
indicates normal expression levels.
(C and D) ERK and VEGFR2 (Y1175) phosphoryla-
tion after knockdown of the indicated phosphatases
shown by immunoblotting (C). Quantification of
pERK activation is shown in (D) (n = 3, mean ± SD,
*p < 0.05).
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endosomes, an intracellular trafficking process that utilizes syn-
ectin/myosin VI complexes (Eichmann and Simons, 2012). The
previous puzzle surrounding VEGFR2 trafficking was how a
VEGFR2-containing endosome could be coupled to the synec-
tin/myosin-VI motor, given the absence of a PDZ binding domain
in the receptor. Here we show that this role is played by NRP1 via
its PDZ-based interaction with synectin.
Synectin has two principle protein interaction sites, a PDZ2
and amyosin VI binding domain. Through the PDZ2 site, synectin
interacts not only with NRP1, but also with other transmembrane
proteins, such as syndecan-4 and the TRK receptors (De Vries
et al., 1998; Gao et al., 2000; Lou et al., 2001). These interactions
promote specific signaling events, such as syndecan 4-depen-
dent activation of RhoG and Rac1 (Elfenbein et al., 2009) and
IGF1-dependent ERK activation (Booth et al., 2002; Lou et al.,
2001) in EC or BDNF-stimulated synaptic transmission in hippo-
campal neurons (Yano et al., 2006). By bindingmyosin VI, synec-
tin then mediates inward endosomal vesicle trafficking in a
number of different cell types, including EC (Naccache et al.,
2006; Varsano et al., 2006). Because synectin/myosin-VI-medi-
ated trafficking is particularly important to promote VEGFR2
signaling in arterial EC, the knockout of either synectin or myosin
VI results in arterial-specific morphogenic defects characterized
by a smaller number of arteries, decreased lumen sizes, and
reduced branching complexity of the arterial tree, both during
development and in adult tissues (Chittenden et al., 2006; Lana-
han et al., 2010).
Mechanistically, impaired VEGFR2 trafficking in synectin null
EC leads to prolonged retention of VEGFR2 in a previously un-
identified cytoplasmic compartment containing PTP1b, a phos-
phatase that targets the Y1175 site of VEGFR2 to reduce ERK
activation. As VEGFR2 cannot directly interact with synectin to
facilitate its trafficking away from PTP1b, another molecule
must be involved. A likely candidate has been NRP1, as it inter-164 Developmental Cell 25, 156–168, April 29, 2013 ª2013 Elsevier Inc.acts with both VEGFR2 and synectin bio-
chemically (Cai and Reed, 1999; Soker
et al., 2002), and because NRP1-VEGFR2
complex formation on the plasma cell
membrane of EC in vitro requires the
PDZ-binding domain of NRP1 (Prahst
et al., 2008). Our study provides direct evi-dence that the interaction of NRP1 with both VEGFR2 and syn-
ectin is functionally significant and specifically important for
arteriogenesis.
A previous study in EC that overexpressed VEGFR2 and NRP1
supports a critical role for the NRP1 cytoplasmic domain inmedi-
ating VEGFR2 trafficking (Ballmer-Hofer et al., 2011). In these ex-
periments, the NRP1-binding isoform of VEGF-A, VEGF-A165a,
directed VEGFR2 to the Rab5/Rab4/Rab11 recycling pathway
in a NRP1-dependent fashion, whereas the non-NRP1-binding
isoform VEGF-A165b directed VEGFR2 toward degradation via
the Rab7 pathway. Moreover, NRP1 targeting of endocytosed
VEGFR2 to the Rab5/Rab11 pathway requires the presence of
the NRP1 PDZ binding domain (Salikhova et al., 2008), suggest-
ing a synectin-dependent process. We have now extended
these observations by demonstrating that NRP1 promotes the
transition of VEGFR2 from Rab5+ sorting to EAA1+ endosomes
in a pathway that requires the NRP1 synectin-binding domain to
stimulate ERK signaling for arteriogenesis. Thus, the reduced
appearance of VEGFR2/NRP1 complexes in EEA1+ endosomes
is due to a combination of an upstream defect, a delay in traf-
ficking from Rab5+ sorting endosomes, and a downstream
defect, the increased clearance of the complex to Rab7+, but
not Rab11+ compartments.
We further confirmed with SIM imaging that the endocytosed
VEGFR2/NRP1 complex is found in a complex with PTP1b in
Rab5+ sorting endosomes that have a characteristic toroid
appearance, i.e., before it enters EAA1+ endosomes. The
reduced level of VEGFR2 phosphorylation on Y1175 we observe
in Nrp1cyto EC can therefore be explained by prolonged expo-
sure to PTP1b and agrees with the kinetics of delayed VEGFR2
trafficking in synectin null EC (Lanahan et al., 2010) and the
fact that PTP1b knockdown restored VEGFR2 Y1175 phosphor-
ylation and ERK activation in both types of mutants.
Reduced VEGF-A-dependent ERK activation in primary EC
and mice lacking the NRP1 cytoplasmic tail was associated
Figure 8. Colocalization of PTP1B, VEGFR2, and NRP1 by SIM Confocal Microscopy and Model of NRP1-Dependent Arteriogenic Signaling
(A) SIM images of primary arterial EC immunolabeled for VEGFR2 and PTP1b 10 min after VEGF-A165 stimulation show colocalization of VEGFR2 and PTP1b in
‘‘donut’’-shaped structures characteristic of early endosomes.
(A0) The top panel shows an endocytic vesicle imaged using structured illuminationmicroscopy and the adjacent graph plots localization of VEGFR2 and PTP1b in
the vesicle. Note the colocalization of VEGFR2 and PTP1b in the donut-shaped structure characteristic of early endosomes. The bottom panel shows the same
endocytic vesicle in (A), but imaged using conventional microscopy, and the adjacent graph plots localization of VEGFR2 and PTP1b in the vesicle; note the
superior resolution of SIM. Scale bar represents 20 mm.
(B) SIM images of primary arterial EC formWT andNrp1cytomice immunolabeled for VEGFR2 andNRP1 15min after VEGF-A165 stimulation show colocalization of
VEGFR2 and NRP1 in both cell types.
(C) Model of NRP1-dependent arteriogenic signaling. VEGF-A165 binding to VEGFR2 and NRP1 on the plasma membrane induces complex formation between
the threemolecules and leads to clathrin-mediated endocytosis. Phosphorylation of Y1175 in VEGFR2 stimulates ERK signaling, but is inactivatedwhen exposed
to the tyrosine phosphatase PTP1b at the plasma membrane or in RAB5+ endosomes. The NRP1 cytoplasmic domain links the VEGF-A165/VEGFR2/NRP1
complex to myosin VI via synectin to promote trafficking from RAB5+ to EAA1+ endosomes, where VEGFR2maintains its Y1175 phosphorylation in the absence
of exposure to PTP1b and is therefore able to evoke ERK signaling of sufficient amplitude to promote arteriogenesis.
See also Figure S8.
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and impaired tubulogenesis in vitro. The in vitro tubulogenesis
assay offered additional mechanistic insight into NRP1-depen-
dent VEGFR2 trafficking and ERK activation. Thus, reduced
ERK activation in EC expressing NRP1cyto could be corrected
by expressing full-length NRP1, but not NRP1 lacking the PDZ
domain, consistent with the idea that this domain regulates
VEGFR2 trafficking and ERK signaling via synectin/myosin-VI
recruitment. Moreover, constitutively active ERK effectively
restored tubulogenesis in EC expressing the NRP1cyto mutant
protein. Taken together, these observations support the hypoth-
esis that NRP1/VEGFR2 trafficking-dependent ERK activation is
critical for vascular tubulogenesis in vitro and, by extension,
arteriogenesis in vivo.
Overall, this study supports the concept that robust NRP1/
VEGFR2-mediated ERK activation from the EAA1+ endosomesDeveis central to arterial morphogenesis, but not angiogenesis. Other
data supporting this notion include the direct dependence of
arterial morphogenesis in gridlock zebrafish on the extent of
ERK signaling (Hong et al., 2008; Hong et al., 2006), reduced ar-
teriogenesis in fish andmice after synectin andmyosin-VI knock-
down (Chittenden et al., 2006; Dedkov et al., 2007; Lanahan
et al., 2010), and the ability of a constitutively active ERK mutant
to overcome VEGF-A signaling defects in synectin null mice and
therefore restore normal arterial morphogenesis (Ren et al.,
2010).
In view of these finding, we suggest that VEGF-A regulates
angiogenesis and arteriogenesis via two distinctly different path-
ways. Angiogenesis is controlled by VEGF-A-induced VEGFR2
signaling events that do not require synectin/myosin-VI-depen-
dent endocytosis and trafficking of the VEGFR2/NRP1 complex.
This happens either because it requires lower levels of ERKlopmental Cell 25, 156–168, April 29, 2013 ª2013 Elsevier Inc. 165
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other VEGF-initiated signaling events at the plasma membrane
such as, for example, PI3K/AKT activation. Arteriogenesis, how-
ever, is critically dependent on high level endothelial ERK activa-
tion and therefore requires VEGF-A165-induced NRP1 and
VEGFR2 coendocytosis and subsequent trafficking of the
VEGFR2/NRP1/synectin/myosin-VI complex away from the
plasma membrane and PTP1b associated with Rab5 sorting en-
dosomes to ensure prolonged ERK signaling from EEA1+ endo-
somes (Figure 8C).
EXPERIMENTAL PROCEDURES
Animals
Mice lacking the cytoplasmic tail of NRP1 (Nrp1cyto) have previously been
described (Fantin et al., 2011). All animal husbandry and experiments were
performed in compliance with the guidelines established by institutional review
boards.
Reagents and Antibodies
The following regents were used: transferrin from human serum, Alexa Fluor
488 conjugate (Invitrogen T-13342), human fibronectin (BD Biosciences
356008), VEGF-A165 (293-VE R&D Systems), PTP siRNAs FlexiTube (R-PTP-
mu [PTPRM], DEP1, PTP1B, SHP1 (PTPN6); QIAGEN 1027416), EZ-Link
Sulfo-NHS-SS-Biotin (Pierce 21331), and immobilized Neutravidin protein
(Pierce 29200). Antibodies include rat monoclonal VEGFR2 (Flk-1, clone
Avas12a1 Fitzgerald 10R-6549), goat polyclonal NRP1 (R&D Systems
AF566), goat polyclonal NRP1 (Santa Cruz 7239), goat polyclonal anti-EEA1
(Santa Cruz 6415), rabbit polyclonal anti-EEA1 (Santa Cruz 33585), rabbit
monoclonal Rab5 (Cell Signaling 3547), rabbit monoclonal Rab7 (Cell
Signaling 9367), goat polyclonal anti-VE-cadherin (Santa Cruz SC6458),
anti-phospho-VEGFR2 (Tyr1175, Cell Signaling 2478), anti-total VEGFR2
(Cell Signaling 2479), anti-phospho p44/42 MAP kinase (phospho-ERK,
Cell Signaling 9106), anti-p44/42 MAP kinase (total ERK, Cell Signaling
9102), anti-PTP1b (Upstate 07-088, BD 610139), anti-DEP-1/CD148 (R&D
AF1934), anti-PTPmu (Cell Signaling 4485), and anti-SHP1 (Cell Signaling
3759). We used appropriate secondary antibodies that were conjugated to
horseradish peroxidase (Vector Laboratories) or fluorescently labeled (Life
Technologies).
Adenovirus Rescue of Floxed Nrp1 and Nrp1cyto Endothelial Cells
Floxed Nrp1 EC were grown to 60%–70% confluence on gelatin-coated
dishes and treated with Cre adenovirus overnight in media containing 20%
FBS at a multiplicity of infection of 100. The washed cells or Nrp1cyto EC
were then treated with control CMV, Nrp1cyto, Nrp1PDZ, or full-length NRP1
overnight, washed, grown an additional 2 days, and then starved overnight
in 0.5% FBS. Cells were stimulated for 5 min with 50 ng/ml VEGF-A165 and
lysed in NP40 buffer.
siRNA Transfection of Endothelial Cells
EC were grown to 60–70% confluence on gelatin-coated dishes and treated
on 2 consecutive days for 4 hr with 200 pmol/dish of siRNA (QIAGEN
FlexiTube siRNA or Santa Cruz siRNA) in 2 ml growth media containing
0.5% FBS and TransPass R2 transfection reagent-siRNA suspension (New
England BioLabs). EC were then starved overnight in growth media containing
0.5% FBS, stimulated for 5 min with 50 ng/mlVEGF-A165 and lysed in NP40
buffer.
Colocalization of Transferrin and EEA1
Cells were starved overnight with 0.5% FBS, placed on ice for 20 min, incu-
bated with Alexa Fluor488 conjugated transferrin on ice for 30 min, rinsed
three times with cold PBS and then stimulated with serum at 37C for
various times. After rinsing twice with ice cold PBS pH 2.5, cells were fixed
at room temperature in 4% formaldehyde in PBS for 10 min and permeabi-
lized with 2.5% formaldehyde containing 0.1% Triton X-100 and 0.1% NP-40
for 10 min at room temperature. Cells were then labeled with rabbit anti-166 Developmental Cell 25, 156–168, April 29, 2013 ª2013 Elsevier IEEA1 followed by chicken anti-rabbit Alexa 568 antibody. Samples were
mounted with ProLong Gold DAPI (Life Technologies) and imaged using an
UltraVIEW VoX spinning disc confocal microscope with a 603 oil immersion
lens (Perkin Elmer) and equipped with a Ti-E microscope stand (Nikon). Im-
age analysis was performed using the colocalization module of Volocity
software.
Colocalization of VEGFR2, NRP1, and EEA1 or Rab5, Rab7, Rab11,
and PTP1b
Cells were plated on gelatin-coated glass bottom dishes (MatTek), starved
overnight with 0.5% FBS, and then placed on ice. Cells were incubated with
10 mg/ml rat anti-mouse VEGFR2 and goat anti-rat NRP1 for 15 min and rinsed
three times with cold PBS. Cells were stimulated with 50 ng/mlVEGF-A165,
incubated at 37C for various times, washed twice with ice cold PBS pH 2.5,
rinsed three timeswith cold PBS and then fixed for 10min at room temperature
in 4% formaldehyde in PBS and permeabilized with 2.5% formaldehyde con-
taining 0.1% Triton X-100 and 0.1% NP-40 for 10 min at room temperature.
Cells were labeled with rabbit anti-EEA1 followed by chicken anti-rabbit
Alexa647 secondary antibody. For detection of VEGFR2 and NRP1, cells
were labeled with chick anti-rat alexa488 and donkey anti-goat alexa568 sec-
ondary antibodies. For Rab5, Rab7, and PTP1b costaining, NRP1 primary anti-
body was labeled with chick anti-goat alexa647, whereas primary antibodies
for Rab5 or Rab7 were labeled with anti-rabbit alexa568, and PTP1b with
anti-mouse alexa568. For Rab11 staining, a Rab11-RFP adenovirus was
used to transduce cells prior to labeling. Samples were mounted with ProLong
Gold DAPI and imaged with a Perkin Elmer UltraVIEW VoX spinning disc
confocal microscope equipped with a 603 oil immersion lens and a 14 bit
electron-multiplied, charge coupled device camera (8 mm pixel size; Hama-
matsu C9100-50). Thresholds for z stack images were acquired using the
MaxEntropy automatic threshold method provided by the ImageJ
MultiThresholder plugin of (NIH Bethesda) (Baler, Landini & Rasband). The
overlap coefficient according to Manders was calculated using the ImageJ
colocalization analysis plugin JACoP (Bolte & Cordelieres).
SIM Microscopy
Images were acquired using a U-PLANAPO 603/1.42 PSF, oil immersion
objective lens (Olympus, Center Valley, PA) and CoolSNAP HQ2 CCD cameras
with a pixel size of 0.080 mm (Photometrics, Tucson, AZ) on the OMX version 3
system (Applied Precision) equipped with 488, 561, and 642 nm solid-state la-
sers (Coherent and MPB communications). Samples were illuminated by a
coherent scrambled laser light source that had passed through a diffraction
grating to generate the structured illumination by interference of light orders
in the image plane to create a 3D sinusoidal pattern, with lateral stripes approx-
imately 0.270 nm apart. The pattern was shifted laterally through five phases
and through three angular rotations of 60 for each z section, separated by
0.125 nm. Exposure timeswere typically between 200 and 500ms, and the po-
wer of each laser was adjusted to achieve optimal intensities of between 2,000
and 4,000 counts in a raw image of 16-bit dynamic range, at the lowest
possible laser power to minimize photo bleaching. Raw images were pro-
cessed and reconstructed to reveal structures with 100–125 nm resolution
(Gustafsson et al., 2008). The channels were then aligned in x, y, and rotation-
ally using predetermined shifts as measured using a target lens and the Soft-
worx alignment tool (Applied Precision).
In Vitro Three-Dimensional Endothelial Lumen Formation Assay
As previously described, human umbilical cord EC were cultured in 3D
collagen matrices (2.5 mg/ml) at 2 3 106/ml to assess their ability to form lu-
mens and tubes (Koh et al., 2008). EC were treated twice with 20 nM NRP1
or control siRNA over a 3-day period and then overnight with adenoviral vec-
tors expressing LacZ control, CA ERK, NRP1, NRP1cyto, or NRP1PDZ.
Collagen gels contained 200 ng/ml recombinant stem cell factor, inter-
leukin-3, stromal-derived factor 1a, and FGF-2 (Stratman et al., 2011). The
culture media contained VEGF-A165 and FGF-2 at 40 ng/ml and reduced
serum-supplement II as described (Koh et al., 2008). After 3 days, cultures
were fixed with glutaraldehyde, stained with toluidine blue, and photo-
graphed. EC lumen and tube areas were quantitated from these photographs
by tracing total lumen area in each field using Metamorph software as
described (Koh et al., 2008).nc.
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As previously described (Fantin et al., 2013), dissected E12.5 hindbrain tissue
was fixed in with 4% formaldehyde in PBS on ice, washed, incubated with
serum-free protein block (Dako), and immunolabeled with goat anti-rat
NRP1, goat anti-VEGFR2 (R&D Systems AF566, AF644) or rabbit anti-neurofi-
lament (Millipore AB1981) followed by Alexa488-conjugated goat anti-rabbit
IgG (Molecular Probes) and Cy3-conjugated rabbit anti-goat Fab fragment
(Jackson Immuno). Samples were imaged with a LSM710 laser scanning
confocal microscopes (Zeiss).
Alkaline Phosphatase Fusion Protein Binding Assay
As previously described (Fantin et al., 2013), alkaline phosphatase (AP)-
VEGF165 fusion protein was incubated with freshly dissected E12.5 hindbrain
tissue, washed three times for 20 min each with PBS, fixed with 4% formalde-
hyde in PBS for 1 hr, and washed again. Endogenous AP was heat-inactivated
at 65C for 3 hr. Tissue-bound, heat-stable, recombinant AP activity was de-
tected as an insoluble reaction product after incubation with nitro blue tetrazo-
lium and 5-bromo-4-chloro-3-indolyl phosphate (Roche) in a buffer containing
100 mM Tris pH 9.5, 100 mM NaCl, and 5 mM MgCl2. Images were recorded
using anMZ16microscope (Leica) equipped with aMicropublisher 3.3 camera
(Q Imaging).
Statistical Analysis
All data are shown asmean ± SEMor SD as bars in the histograms. Differences
were considered statistically significant if p% 0.05 by Student’s t test.SUPPLEMENTAL INFORMATION
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